Skip to main content

Table 3 Factors associated with the occurrence of neurological severe adverse effects following ivermectin treatment in DRC between 2003 and 2017 – univariate analysis

From: Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo

Parameter category

% NSAE

Crude OR (95%-CI)

P-value

Sex

 Male

509 (76.0)

3.9 (2.9–5.4)

< 0.001

 Female

122 (44.4)

1

 

Age (years)

  ≤ 18

14 (22.2)

1

 

 19–35

301 (74.7)

10,3 (5.5–19.5)

< 0.001

  ≥ 36

316 (65.9)

6.8 (3.6–12.7)

< 0.001

Alcohol consumption 24 h before ivermectin treatment

 Yes

181 (87.9)

4.6 (2.9–7.6)

< 0.001

 No

450 (60.9)

1

 

Hemp consumption 24 h before ivermectin treatment

 Yes

89 (80.9)

2.3 (1.4–3.9)

< 0.001

 No

542 (64.9)

1

 

Associated diseases

 Loiasis

   

 Yes

590 (68.8)

2.5 (1.6–3.9)

< 0.001

 No

41 (46.6)

1

 

Uncomplicated malaria

 Yes

610 (66.7)

1

 

 No

21 (70.0)

1.2 (0.5–2.6)

0.703

Diabetes

 Yes

12 (100.0)

NA

 

 No

619 (66.4)

  
  1. NSAE = neurological severe adverse effects, OR = odds ratio, CI = confidence interval